- Featured Product
- KD/KO Validated
c-Met (Cytoplasmic) Polyclonal antibody
c-Met (Cytoplasmic) Polyclonal Antibody for IHC, IP, WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (2)
Applications
WB, IP, IHC, IF, ELISA
Conjugate
Unconjugated
Cat no : 25869-1-AP
Synonyms
Validation Data Gallery
Tested Applications
| Positive WB detected in | A431 cells, HepG2 cells |
| Positive IP detected in | HeLa cells |
| Positive IHC detected in | human breast cancer tissue, human colon tissue, human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:200-1:1000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Sample-dependent, check data in validation data gallery | |
Published Applications
| KD/KO | See 1 publications below |
| WB | See 13 publications below |
| IHC | See 1 publications below |
| IF | See 1 publications below |
| IP | See 1 publications below |
Product Information
The immunogen of 25869-1-AP is c-Met (Cytoplasmic) Fusion Protein expressed in E. coli.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | c-Met (Cytoplasmic) fusion protein Ag23140 |
| Full Name | met proto-oncogene (hepatocyte growth factor receptor) |
| Calculated molecular weight | 1390 aa, 155 kDa |
| Observed molecular weight | 145 kDa |
| GenBank accession number | BC130420 |
| Gene symbol | MET |
| Gene ID (NCBI) | 4233 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| Storage Buffer | PBS with 0.1% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
c-Met (also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target (PMID: 26036285). The c-met receptor is a 190-kD glycoprotein consisting of a 145-kD membrane-spanning beta chain and a 50-kD alpha chain (PMID: 7806559). In Western blot, this antibody produces bands of unknown identity at 55 and 100 kDa.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for c-Met (Cytoplasmic) antibody 25869-1-AP | Download protocol |
| IHC protocol for c-Met (Cytoplasmic) antibody 25869-1-AP | Download protocol |
| IP protocol for c-Met (Cytoplasmic) antibody 25869-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Autophagy The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
| ||
Front Oncol SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis. | ||
Kaohsiung J Med Sci Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met. | ||
Thorac Cancer CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma. | ||
Invest New Drugs Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors. |
